Asterand

Press: Asterand rose after its Bioseek subsidiary, the developer of a platform that predicts drug responses, renewed a collaboration with Merck... read more

Press: Asterand rose after its Bioseek subsidiary, the developer of a platform that predicts drug responses, renewed a collaboration with Merck of Germany.Asterand said this month that it remained in talks with potential bidders, having put itself up for sale in October.Source - Financial Times

Press: 31.08.11: -4.73, (4.15) Press: Asterand fell after warning there was ?significant doubt? that it could continue as a going concern.... read more

Press: 31.08.11: -4.73, (4.15) Press: Asterand fell after warning there was ?significant doubt? that it could continue as a going concern. Worse-than-expected trading would result in a breach of its banking covenants and full-year results would be ?materially lower than market expectations?. Source - Mail

Daniel Stewart raises Asterand target to 21p from 19p, after the medical research company won a new contract. Asterand won a $24.3... read more

Daniel Stewart raises Asterand target to 21p from 19p, after the medical research company won a new contract. Asterand won a $24.3 million contract with the National Cancer Institute, under which it will supply the NCI with clinically annotated human biospecimens. "Not only is this contract expected to push Asterand back into profitability, but it also further demonstrates the group?s success at expanding its work with government institutions," Daniel Stewart says. The rating is unchanged at buy.

02.10.10: Asterand rose 1.00p to 12.25p after winning a $24.3m five-year contract with the National Cancer Institute to supply... read more

02.10.10: Asterand rose 1.00p to 12.25p after winning a $24.3m five-year contract with the National Cancer Institute to supply clinically annotated human biospecimens for The Cancer Genome Atlas project.